<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01975935</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00079381</org_study_id>
    <nct_id>NCT01975935</nct_id>
  </id_info>
  <brief_title>Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients</brief_title>
  <official_title>Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves research about an investigational medicine called Amlexanox. The reason
      for this study is to find out how Amlexanox can improve type 2 diabetes, insulin resistance,
      obesity and non-alcoholic fatty liver disease (NAFLD). In this study, Amlexanox is considered
      to be investigational (not approved by the Food and Drug Administration [FDA]) for type 2
      diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). This is
      a placebo controlled study. There is a 50-50 chance that the patient may either receive the
      study drug, Amlexanox, or a placebo (sugar pill). Neither the patient or the study doctors
      will know if the patient is receiving the study drug or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposal focuses on a clinical proof of concept study to evaluate a novel hypothesis. We
      propose that overnutrition, leading to obesity, represents a state of excessive energy
      storage promoted by insulin. The stress of excessive energy storage initiates a set of
      homeostatic responses that includes the generation of adipose tissue and liver inflammation,
      which involves the secretion of proinflammatory cytokines that block energy storage in fat
      and liver by inducing insulin resistance, thus relieving stress on the adipocyte and
      hepatocyte. However, our recent data suggest that inflammation itself is countered by a
      secondary feedback loop, which we have termed &quot;counter-inflammation&quot;. We propose that this
      process keeps inflammation in check, ensuring that it is maintained at low levels. At the
      same time counter-inflammation also promotes energy conservation via increased energy storage
      and decreased utilization in a manner that is insulin-independent. We hypothesize that the
      noncanonical IkB kinases Ikke and TBK1 are &quot;counterinflammatory&quot; kinases that feedback
      inhibit inflammatory pathways while helping to support a positive energy balance.

      How can this hypothesis be addressed in human subjects? A number of clinical trials have
      already been initiated with the intention of improving insulin resistance by attenuating
      inflammation. Many of these have focused on the blockade of single cytokines or their
      receptors such as TNFa, IL1 and MCP1 (CCR2 antagonist). While the record on these trials is
      mixed, the complexity of inflammatory pathways elicited during obesity suggests that
      inhibition of only a single cytokine is not likely to be sufficient. Additionally, because
      numerous studies have implicated the NFkB pathway in obesity-induced inflammation, NFkB
      inhibitors have been contemplated. Salsalate was originally resuscitated due to its perceived
      activity to block NFkB and hence to block inflammation. However, although clinical studies on
      this drug have been promising, precisely how salsalate works, what its target is, and whether
      it actually functions an NFkB inhibitor remains controversial (recent data indicate that it
      may act via activation of AMPK).

      We describe here a new potential therapeutic agent that is the result of an academic
      collaborative drug discovery effort carried out at the University of Michigan. Our studies on
      elucidating the role of NFkB in insulin resistance and macrophage activation led to the
      identification of Ikke and TBK1 as potential targets for therapeutic intervention in obesity
      and type 2 diabetes. We performed a high throughput screen searching for inhibitors of these
      kinases, evaluating a group of 175,000 compounds that included a collection of approved
      drugs. Interestingly, the most potent and specific inhibitor discovered was amlexanox; an
      older drug originally developed in Japan for the treatment of asthma and allergic rhinitis,
      and later in the US for aphthous ulcers, but without a well understood mechanism of action.
      It has been in use since 1987, and has a favorable side effect profile.

      This protocol is the first proof of concept study to evaluate the possible repurposing of
      Amlexanox for the treatment of type 2 diabetes and obesity. At the same time, we hope to test
      the hypothesis that IKKe and TBK1 may be important players in maintaining a positive energy
      balance, and also in supporting insulin resistance, during prolonged over-nutrition. Finally,
      these studies will also provide valuable insight into the validity of these two protein
      kinases as drug targets for the future development of new chemical entities useful in the
      treatment of type 2 diabetes. Therefore our specific aims are

        1. Does amlexanox treatment improve measures of type 2 diabetes, insulin resistance and
           obesity? To address this question, we intend to treat patients with clinical Type 2
           diabetes and Grade 1/2 obesity (BMI 27 to 45 kg/m2) for a period of 3 months in a
           double-blinded placebo controlled proof-of concept study. We will enroll 40 patients
           without evidence of severe end-organ damage from chronic complications of Type 2
           diabetes who also are on metformin and/or DPPIV inhibitors or no medications, who also
           have clear-cut evidence of hyperglycemia (HbA1c&gt;6.5% and &lt;10.0%). These patients will be
           treated with either placebo or Amlexanox oral tablets at a starting dose of 25 mg PO tid
           for 2 weeks and then titrated up to a dose of 50 mg PO tid (doses used to treat asthma
           in humans and leading to serum concentrations comparable to metabolically effective
           doses in rodent studies) for the remainder of the therapy period. HbA1c is targeted as
           primary end-point in this study. Fasting lipid profiles, plasma insulin, HOMA-IR,
           clinical markers of inflammation and adipocytokine profiles will be measured as other
           parameters of interest at baseline, 6 weeks and 12 weeks. Insulin secretion as well as
           insulin sensitivity will be probed using a mixed meal test. Weight is also an important
           but secondary end-point in this study. We will determine resting energy expenditure with
           indirect calorimetry and total body composition using DEXA at baseline and 12 weeks.
           Safety monitoring with CBC, comprehensive metabolic biochemistry, CPK and urine analyses
           will be undertaken at 1, 2, 4, 6, and 12 weeks, and urinary albumin at baseline and 12
           weeks. Measures of safety and efficacy will be repeated 4 weeks after the drug has been
           discontinued as well.

        2. Does amlexanox treatment improve measures of NAFLD in obese patients? All participants
           in the clinical proof-of-concept study outlined in the aim above will be studied for the
           degree of steatosis in the liver with the use of MRI and MR spectroscopy at baseline and
           at 3 months of the study.

        3. Development of biomarkers for treatment of patients with type 2 diabetes by amlexanox.
           We will evaluate the phosphorylation of proteins known to be targets of IKKe and TBK1 in
           blood, and adipose tissue samples. We will use phospho-specific antibodies to evaluate
           the regulation of targets that play a role in energy metabolism, and also in feedback
           inhibition of NFkB. These studies will pave the way for future evaluations probing the
           metabolic relevance of IKKe and TBK1 in humans using the same agent or more potent ones
           to be discovered or designed.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Hemoglobin A1c Values</measure>
    <time_frame>12 weeks (measured at baseline and 12 weeks)</time_frame>
    <description>Difference in hemoglobin A1c as measured at baseline and week 12 visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic Steatosis as Measured by MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Improvement in hepatic steatosis by MRI is shown by a decrease in percent fat from baseline to week 12 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>12 week</time_frame>
    <description>Change in weight (kilograms) as measured at baseline and week 12 visits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlexanox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlexanox</intervention_name>
    <description>25 mg amlexanox tablets blinded by encapsulation</description>
    <arm_group_label>Amlexanox</arm_group_label>
    <other_name>Solfa tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo sham blinded by encapsulation in the same capsules as the study drug arm</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old at baseline.

          -  Is male, female not of childbearing potential, or meets all the following criteria if
             female of childbearing potential (including perimenopausal women who have had a
             menstrual period within one year):

               -  Not breastfeeding.

               -  Negative pregnancy test result (human chorionic gonadotropin, beta subunit
                  [βhCG]) at baseline (not applicable to hysterectomized females).

               -  Must practice and be willing to continue to practice appropriate birth control
                  (defined as a method which results in a low failure rate when use consistently
                  and correctly, such as implants, injectables, oral contraceptives, some
                  intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a
                  vasectomized partner) during the entire duration of study period.

          -  Has physician-confirmed diabetes mellitus with a clear diagnosis or per ADA criteria
             with fasting glucose&gt;126 mg/dL or HbA1c &gt;6.4% or 2 hour GTT &gt;200 mg/dL.

          -  BMI ≥27 and &lt;45 kg/m2.

          -  On no medications or only on first line oral medications (such as Metformin and/or DPP
             IV inhibitors) for treatment of Type 2 diabetes mellitus with a stable regimen for &gt;12
             weeks.

          -  Alcohol consumption of less than 40 grams/week.

          -  A liver US confirming presence of fatty infiltration of the liver.

          -  Is able to read, understand and sign the U of M IRBMED approved informed consent form
             (ICF), communicate with study physician and study team, understand and comply with
             protocol requirements.

        Exclusion Criteria:

          -  On insulin, or other injectables for treatment of Type 2 diabetes.

          -  Unable to conduct home based glucose monitoring.

          -  HbA1c &lt;6.5% and &gt;10.0% (set to achieve uniformity in the study population).

          -  Presence of advanced liver disease (as evidenced by abnormal synthetic function,
             abnormal PT or albumin).

          -  Evidence of other etiologies of viral hepatitis.

          -  Presence of hematologic, bone marrow and/or other abnormalities.

          -  Presence of hemoglobinopathy or other hematological abnormalities that will interfere
             with accurate measurement of HbA1c.

          -  Presence of HIV infection.

          -  Inability to give informed consent.

          -  Presence of ESRD, any type of active cancer, or &gt;class 2 congestive heart failure
             ((New York Heart Association Functional Classification System), based on medical
             history and physical examination.

          -  Active chronic infection such as known chronic osteomyelitis or tb, etc. (may be
             transient).

          -  Creatinine &gt;1.5 mg/dL.

          -  Proliferative diabetic retinopathy, nonproliferative retinopathy is allowed.

          -  Unable to ambulate.

          -  Clinically relevant CAD: history of stent, CABG or cardiologist confirmed angina.

          -  Any other condition in the opinion of the investigators that may impede successful
             data collection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2013</study_first_submitted>
  <study_first_submitted_qc>October 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2013</study_first_posted>
  <results_first_submitted>March 28, 2017</results_first_submitted>
  <results_first_submitted_qc>March 28, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2017</results_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Elif Oral</investigator_full_name>
    <investigator_title>Associate Professor, Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>diabetes mellitus type 2</keyword>
  <keyword>non-alcoholic fatt liver disease</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlexanox</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
Placebo</description>
        </group>
        <group group_id="P2">
          <title>Amlexanox</title>
          <description>Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
Amlexanox</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
Placebo</description>
        </group>
        <group group_id="B2">
          <title>Amlexanox</title>
          <description>Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
Amlexanox</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.24" spread="7.65"/>
                    <measurement group_id="B2" value="55.81" spread="9.52"/>
                    <measurement group_id="B3" value="57.52" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decline to Answer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Difference in Hemoglobin A1c Values</title>
        <description>Difference in hemoglobin A1c as measured at baseline and week 12 visits</description>
        <time_frame>12 weeks (measured at baseline and 12 weeks)</time_frame>
        <population>The number of participants analyzed at week 12 differs from the overall number analyzed at baseline because 1 treatment group and 3 placebo group participants dropped from the study before their week 12 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Amlexanox</title>
            <description>Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
Amlexanox</description>
          </group>
        </group_list>
        <measure>
          <title>Difference in Hemoglobin A1c Values</title>
          <description>Difference in hemoglobin A1c as measured at baseline and week 12 visits</description>
          <population>The number of participants analyzed at week 12 differs from the overall number analyzed at baseline because 1 treatment group and 3 placebo group participants dropped from the study before their week 12 visit.</population>
          <units>percentage of hemoglobin glycated</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.77" spread="1.07"/>
                    <measurement group_id="O2" value="7.68" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.76" spread="1.23"/>
                    <measurement group_id="O2" value="7.44" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>This is the calculated p value and not the threshold for statistical significance.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Steatosis as Measured by MRI</title>
        <description>Improvement in hepatic steatosis by MRI is shown by a decrease in percent fat from baseline to week 12 visit.</description>
        <time_frame>12 weeks</time_frame>
        <population>One placebo patient was an early termination and did not have an MRI scan done at the 12 week visit. A total of 20 patients received MRI scans due to funding limitations.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Amlexanox</title>
            <description>Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
Amlexanox</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Steatosis as Measured by MRI</title>
          <description>Improvement in hepatic steatosis by MRI is shown by a decrease in percent fat from baseline to week 12 visit.</description>
          <population>One placebo patient was an early termination and did not have an MRI scan done at the 12 week visit. A total of 20 patients received MRI scans due to funding limitations.</population>
          <units>% fat</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.82" spread="7.82"/>
                    <measurement group_id="O2" value="18" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.88" spread="8.66"/>
                    <measurement group_id="O2" value="16.22" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <description>Change in weight (kilograms) as measured at baseline and week 12 visits.</description>
        <time_frame>12 week</time_frame>
        <population>The number of participants analyzed at week 12 differs from the overall number analyzed at baseline because 1 treatment group and 3 placebo group participants dropped from the study before their week 12 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
Placebo</description>
          </group>
          <group group_id="O2">
            <title>Amlexanox</title>
            <description>Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
Amlexanox</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>Change in weight (kilograms) as measured at baseline and week 12 visits.</description>
          <population>The number of participants analyzed at week 12 differs from the overall number analyzed at baseline because 1 treatment group and 3 placebo group participants dropped from the study before their week 12 visit.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.24" spread="19.77"/>
                    <measurement group_id="O2" value="100.95" spread="15.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.94" spread="18.83"/>
                    <measurement group_id="O2" value="100.81" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.51</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>March 31, 2014-May 25, 2017. 2 years, 2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo tablet (TID) 2 weeks Placebo tablets (2 x TID) 10 weeks
Placebo</description>
        </group>
        <group group_id="E2">
          <title>Amlexanox</title>
          <description>Solfa tablets (Amlexanox 25mg) TID for 2 weeks Solfa tablets (Amlexanox 25mg x 2) TID for 10 weeks
Amlexanox</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>NSTEMI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injured left leg playing football</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Head cold</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated CK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Itchy skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Optimal drug dose is yet to be defined. The dose and the treatment duration may not have been sufficient to reveal all the positive as well as negative effects of the drug. Effects of combination with other anti-diabetics is also unknown.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Elif Oral</name_or_title>
      <organization>University of Michigan</organization>
      <phone>7346157271</phone>
      <email>eliforal@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

